Visgenx Appoints William Pedranti as Chief Executive Officer

The Company is developing VGX-0111, a gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leading cause of vision loss SAN DIEGO, June 5, 2023 -- (Healthcare Sales & Marketing Network) -- Visgenx, Inc.... Regenerative Medicine, Ophthalmology, Personnel Visgenx , dry AMD, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news